| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics
|
Li, Jianke
|
|
2019
|
84 |
4 |
p. 799-807
|
artikel
|
| 2 |
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
|
Clarke, Jeffrey Melson
|
|
2019
|
84 |
4 |
p. 909-917
|
artikel
|
| 3 |
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
|
Mirza, Mansoor Raza
|
|
2019
|
84 |
4 |
p. 791-798
|
artikel
|
| 4 |
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
|
Mehnert, Janice M.
|
|
2019
|
84 |
4 |
p. 899-907
|
artikel
|
| 5 |
A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma
|
Vornicova, Olga
|
|
2019
|
84 |
4 |
p. 919-923
|
artikel
|
| 6 |
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer
|
Peer, Cody J.
|
|
2019
|
84 |
4 |
p. 759-770
|
artikel
|
| 7 |
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells
|
Burns, Kathryn E.
|
|
2019
|
84 |
4 |
p. 739-748
|
artikel
|
| 8 |
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study
|
Zheng, Song
|
|
2019
|
84 |
4 |
p. 819-827
|
artikel
|
| 9 |
Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway
|
Cha, Zhe
|
|
2019
|
84 |
4 |
p. 719-728
|
artikel
|
| 10 |
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer
|
Mouri, Atsuto
|
|
2019
|
84 |
4 |
p. 873-880
|
artikel
|
| 11 |
Current status of nanomedicine in the chemotherapy of breast cancer
|
Fraguas-Sánchez, A. I.
|
|
2019
|
84 |
4 |
p. 689-706
|
artikel
|
| 12 |
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial
|
Esteva, F. J.
|
|
2019
|
84 |
4 |
p. 839-847
|
artikel
|
| 13 |
FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
|
Xing, Mingyou
|
|
2019
|
84 |
4 |
p. 861-872
|
artikel
|
| 14 |
Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines
|
Min, Dong-Joon
|
|
2019
|
84 |
4 |
p. 771-780
|
artikel
|
| 15 |
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
|
Aslanis, Vassilios
|
|
2019
|
84 |
4 |
p. 749-757
|
artikel
|
| 16 |
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
|
Roviello, G.
|
|
2019
|
84 |
4 |
p. 669-677
|
artikel
|
| 17 |
Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
|
Reddick, Samuel J.
|
|
2019
|
84 |
4 |
p. 829-838
|
artikel
|
| 18 |
Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
|
Reddick, Samuel J.
|
|
|
84 |
4 |
p. 829-838
|
artikel
|
| 19 |
Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma
|
Kondo, Eisei
|
|
2019
|
84 |
4 |
p. 849-860
|
artikel
|
| 20 |
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
|
Ogasawara, Ken
|
|
2019
|
84 |
4 |
p. 891-898
|
artikel
|
| 21 |
Population pharmacokinetics of trabectedin in adolescent patients with cancer
|
Poggesi, Italo
|
|
2019
|
84 |
4 |
p. 707-717
|
artikel
|
| 22 |
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
|
Kim, Mi Na
|
|
2019
|
84 |
4 |
p. 809-817
|
artikel
|
| 23 |
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study
|
Rothschild, Sacha I.
|
|
2019
|
84 |
4 |
p. 881-889
|
artikel
|
| 24 |
Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
|
Roys, Annie
|
|
2019
|
84 |
4 |
p. 679-688
|
artikel
|
| 25 |
Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft
|
Fontaine, Shaun D.
|
|
2019
|
84 |
4 |
p. 729-738
|
artikel
|
| 26 |
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
|
Munárriz, Javier
|
|
2019
|
84 |
4 |
p. 781-789
|
artikel
|
Tijdschrift beschrijving